Antiviral drug developer ReViral has secured series B funding in a round co-led by Novo Ventures that included Brace Pharma Capital.
Novo Ventures, a strategic investment subsidiary of pharmaceutical firm Novo, co-led a $55m series B round for ReViral, the UK-based developer of a treatment for a respiratory virus, on Wednesday.
Healthcare-focused venture capital firm New Leaf Venture Partners co-led the round, which included Brace Pharma Capital, the corporate venturing arm of pharmaceutical company EMS, as well as Perceptive Advisors, Andera Partners and OrbiMed.
ReViral is developing an oral treatment for respiratory syncytial virus (RSV), a virus similar to the common…
